With the expanded funding, AI Airlock is expected to scale its operations and support the development of sustainable regulatory pathways for AI-driven medical technologies. Delivered through collaboration between MHRA, DHSC, the NHS AI Team, and Team AB, the programme aligns with broader government strategies, including the AI Opportunities Action Plan, the Regulatory Action Plan, the 10-Year Health Plan, and the Life Sciences Sector Plan.

Commenting on the development, James Pound, Executive Director, Innovation and Compliance, said:
“Securing this multi-year funding boost marks a pivotal moment for AI Airlock and for the safe and responsible advancement of AI in healthcare.
The programme has already shown how collaborative, real-world testing can uncover regulatory challenges early and help innovators bring high-quality, safe technologies to patients faster.
This additional investment will allow us to scale up and ultimately strengthen our ability to ensure that AI-powered medical devices can reach patients safely, efficiently and with the confidence of robust regulatory oversight.”

The AI Airlock programme has evolved steadily since its pilot launch in 2024, followed by a second phase in 2025 that broadened its scope. Early findings highlighted new regulatory complexities associated with AI medical devices, particularly around risk management, accuracy, and the need to anchor model outputs in verified clinical data. It also underscored the importance of explainability in AI systems to strengthen clinician trust, alongside the necessity for continuous post-market monitoring to detect performance shifts or over-reliance.

Building on these insights, the second phase has examined specific regulatory challenges, including AI-powered diagnostic tools, pre-determined change control plans (PCCPs), and evolving use cases of AI systems. The programme has tested a wide spectrum of technologies such as large language models, voice-enabled tools, and advanced diagnostics targeting cancer and rare diseases. Outputs from this phase, including reports and case studies, are expected in Summer 2026 and will guide the design of phase three. Findings are also feeding into the National AI Commission’s work on shaping future regulatory frameworks. As AI Airlock expands, it continues to play a central role in strengthening collaboration between regulators and industry, supporting safe innovation while maintaining a robust and future-ready regulatory environment for medical devices.

At the operational level, the BD® Pyxis™ Pro Dispensing Solution is engineered to improve how medications are stored, accessed, and managed within hospital environments. Its modular, stackable design allows for increased storage capacity within the same physical footprint, accommodating both refrigerated and ambient medications. This approach supports healthcare systems in adapting to shifting patient needs while maintaining consistent medication availability. Enhanced security features such as RFID badge scanning, wireless barcode scanners, and illuminated bins aim to strengthen controlled substance management and simplify medication retrieval processes. In this context, the AI medication dispensing system is positioned as a tool to reduce inefficiencies and disruptions across clinical workflows.

The expansion also includes plans to extend the AI-enabled BD Incada™ Analytics platform already established in the United States to European hospitals and health systems next year. Built on Amazon Web Services’ (AWS) on-demand cloud computing infrastructure, the BD Incada™ Platform integrates advanced AI capabilities, including natural language search in analytics. The system is designed to scale alongside the data generated by nearly three million connected BD devices, offering clinicians enterprise-wide visibility into medication inventory through customizable dashboards. These capabilities support pattern identification, improved medication availability, reduced waste, and enhanced labor efficiency.

To address regional requirements, BD will utilize the AWS European Sovereign Cloud, enabling EU healthcare systems to meet digital sovereignty standards while maintaining performance, security, and scalability. “BD’s innovations in medication management are setting a new standard for unified, data-driven healthcare operations,” said Esteban Rossi, vice president and general manager for Medication Management Solutions, EMEA at BD. “Delivering the BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Platform directly to European hospitals empowers our customers to strengthen medication availability, improve efficiency and enhance patient care.” The Pyxis™ Pro Dispensing Solution is expected to be deployed across Europe in the coming months, with support for 15 languages.

The strategy, titled AI for Care establishes a national framework for the safe, responsible, and effective use of AI across the health system. The initiative sets out four strategic pillars clinical care, operations, research and innovation, and public health and positions AI as a key enabler of healthcare system transformation.

According to the government, the strategy is intended to modernise healthcare services through faster diagnoses, improved patient flow, earlier disease detection, reduced administrative workloads, and greater consistency in care delivery across the country.

Carroll MacNeill, minister for health, described the initiative as a structured roadmap for integrating emerging technologies into healthcare delivery while maintaining strong governance and clinical oversight.

“AI for Care marks an important step toward creating a safer, smarter, and more sustainable healthcare service,” MacNeill said.

“It provides a clear and practical roadmap for adopting AI in ways that are safe, transparent, truly enhance patient care, and support clinicians.

“The strategy focuses on using technology to strengthen, rather than replace the vital human relationships at the core of healthcare.”

The strategy emphasises safeguards around AI deployment, including mandatory human oversight, alignment with the EU AI Act, and forthcoming national guidance from the Health Information and Quality Authority (HIQA).

Clinical and operational applications

The government outlined several areas where AI technologies will be applied to support clinical practice and hospital operations. Certified AI systems will assist radiologists in analysing medical images more rapidly, enabling earlier detection of conditions such as strokes, cancers and fractures.

Other proposed applications include AI-supported discharge planning, AI scribe tools to automate clinical documentation, screening tools for early disease detection, and predictive analytics to forecast demand and improve resource allocation.

The strategy also identifies AI tools that can support clinicians by improving diagnostic accuracy, personalising treatment plans, and providing decision-support capabilities.

AI tools are also expected to play a role in documenting medical records by capturing and summarising clinical encounters, producing discharge summaries and correspondence, and translating medical terminology.

Beyond clinical care, operational uses include predicting patient flow, improving scheduling, allocating hospital resources more effectively, and automating routine administrative tasks. The strategy also highlights the use of AI in forecasting demand, reducing waste, and supporting supply chain management within healthcare systems.

Research, innovation and public health

In research and innovation, AI will be used to streamline ethical approvals, automate evidence appraisal, optimise data integrity, and support clinical audit processes. Automated collection of clinical data from electronic health records (EHRs) and imaging systems is also planned to accelerate research and quality improvement initiatives.

For public health, the strategy outlines the use of AI-driven analytics to support population health surveillance, predictive modelling, and population-based screening programmes.

More accurate processing of evidence and health data is expected to enable better healthcare planning and reduce variation in care delivery across regions.

To support implementation, the HSE plans to publish an AI Implementation Framework to guide consistent deployment across health regions.

Phased implementation

The government outlined a phased rollout plan beginning with applications that have already demonstrated proven results. In the first year, deployments will focus on clinical diagnostics, reducing administrative workloads, improving demand forecasting, and increasing operational productivity.

During years two and three, the strategy aims to scale successful implementations, improve patient experience, advance diagnostic capabilities, optimise treatment pathways, and translate research outcomes into clinical applications.

Years four and five will explore additional AI opportunities as the technology evolves, with the goal of integrating successful innovations into routine health service operations.

Broader digital transformation

The strategy forms part of a wider digital transformation agenda within Ireland’s health system.

Recent initiatives include the rollout of virtual care programmes designed to relieve hospital capacity pressures. Two pilot acute virtual wards at St. Vincent’s University Hospital and University Hospital Limerick recorded 1,500 admissions, equating to 13,800 virtual bed days.

Additional virtual wards have since been launched at Our Lady of Lourdes Drogheda, Midland Regional Hospital Tullamore, Mercy Hospital Cork, and St Luke’s Hospital Kilkenny, with a fifth planned at Galway University Hospital in early 2026.

Separately, procurement is set to begin for a national Electronic Health Record (EHR) system following government approval. The programme will establish a single integrated digital health record for every patient in Ireland, with vendor shortlisting and tender processes now underway and phased implementation planned across all health regions.

Minister MacNeill described the EHR initiative as a “landmark step” in building a more connected health service.

“The National Electronic Health Record programme will be central to patients receiving safer, faster, and more integrated care, supporting clinicians and improving outcomes for everyone,” she said.

Alongside these initiatives, the government has also published a national digital mental health strategy focused on expanding access to digital tools, strengthening governance frameworks, and building a digitally enabled workforce across the health system.

“At MiniMed, every advancement begins with listening to the needs of people living with diabetes,” said Que Dallara, CEO of MiniMed. “By offering more sensor flexibility within a fully integrated system backed by the proven clinical outcomes of our MiniMed™ 780G system1,2,3,4 we’re helping lighten the burden of daily management and giving individuals the freedom to choose what works best for them.”

The MiniMed 780G system already supports the Guardian™ 4 and Simplera Sync™ sensors, each designed to provide up to seven days of wear time. Following the latest approval, the system will also operate with the Instinct sensor, which has been developed exclusively by Abbott for MiniMed’s automated insulin delivery (AID) system. The Instinct sensor is described as the world’s smallest, thinnest and most discreet continuous glucose monitoring (CGM) sensor and can be worn for up to 15 days.

With the addition of the Instinct sensor, individuals using the MiniMed™ 780G system can now select between sensors offering either 7-day or 15-day wear durations, enabling greater flexibility depending on personal preference and lifestyle requirements. MiniMed plans to introduce the MiniMed™ 780G system with the Instinct sensor commercially in the first European countries during the summer of 2026. The company also intends to showcase the complete system at the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2026) scheduled to take place in Barcelona from March 11–14, 2026. In Europe, the MiniMed™ 780G system is indicated for individuals aged two years and older with insulin-requiring diabetes (type 1 and type 2) whose total daily insulin dose is six units or more, and the system is also CE marked for use during pregnancy.

Addressing the Human Crisis in Modern Medicine

The healthcare sector is currently facing a human resources crisis of unprecedented scale, where the implementation of healthcare workforce technology supporting care teams has become a moral and operational imperative. For years, clinicians have been overburdened by manual administrative tasks, fragmented communication, and rigid scheduling practices that lead to chronic fatigue and a loss of professional autonomy. This pervasive burnout not only threatens the mental health of individual practitioners but also directly impacts patient safety and the overall quality of care. A clinical team that is exhausted and disconnected is far more likely to make errors and less able to provide the emotional presence that is essential for a positive patient experience.

The transition toward modern healthcare workforce management begins with a fundamental recognition that the clinician is the hospital’s most valuable asset. Digital tools are now being used to strip away the “administrative friction” that clogs the daily routine of doctors and nurses. By automating the more mundane aspects of hospital operations such as shift bidding, leave management, and credential tracking these systems return valuable time to the care team. This time can then be reinvested in direct patient interaction, leading to higher levels of clinical excellence and professional fulfillment. When the technology works to serve the human staff, the entire institution benefits from a more engaged, resilient, and effective workforce.

The Power of Predictive Workforce Analytics

One of the most transformative aspects of modern hospital staffing technology is the move from reactive to proactive resource management. Workforce analytics healthcare platforms leverage the power of big data to predict future staffing needs with remarkable accuracy. By analyzing variables such as historical patient census data, local public health trends, and even the complexity of the current patient population, these systems can forecast the required clinical capacity several weeks in advance. This allows administrators to adjust staffing levels in a way that ensures every unit is adequately supported without the need for last-minute, high-stress call-outs or the use of expensive agency staff. This predictive capability is a cornerstone of healthcare workforce technology supporting care teams, as it provides a stable and predictable environment for everyone.

Furthermore, these analytics platforms provide deep insights into the well-being of the staff themselves. They can track patterns that correlate with burnout, such as high rates of overtime, frequent shift changes, or a high volume of missed breaks. By identifying these “red flags” early, hospital leadership can intervene with targeted support, whether through adjusting the workload, offering additional resources, or simply providing a much-needed break. This data-driven approach to staff welfare ensures that the institution is as focused on the health of its employees as it is on the health of its patients. In the long run, this proactive care for the clinician is the best way to ensure the long-term sustainability of the medical profession and the safety of the community it serves.

Digital Scheduling and the Rise of Professional Autonomy

A significant driver of professional dissatisfaction in healthcare has historically been the lack of control that clinicians have over their own schedules. Modern digital workforce solutions are changing this by introducing self-service scheduling platforms that prioritize flexibility and autonomy. Through mobile-first applications, staff members can view their schedules, request changes, and pick up additional shifts from anywhere, at any time. These platforms use intelligent algorithms to ensure that every shift is covered by the appropriate mix of skills and experience, while also honoring the personal preferences and work-life balance of the individual. This shift toward a more collaborative and transparent scheduling process is a vital part of healthcare workforce technology supporting care teams.

When clinicians have a voice in when and where they work, they feel more respected and valued by their employer. This increased sense of agency leads to higher levels of job satisfaction and a significant reduction in turnover rates. Furthermore, these platforms can be used to manage “flexible pools” of staff who are willing to work across different departments or locations as needed. This fluidity allows the hospital to be more responsive to sudden changes in patient demand without placing an undue burden on any single team. By utilizing the power of digital connectivity to create a more agile and human-centered scheduling system, healthcare organizations are building a workforce that is ready for the challenges of the 21st century.

Digital Training and Continuous Professional Growth

In the rapidly evolving world of medicine, continuous learning is not just a requirement; it is a necessity for clinical excellence. However, the time required for traditional training can be difficult to find in an already overextended schedule. Modern healthcare workforce technology supporting care teams addresses this by providing on-demand, digital training platforms that deliver bite-sized educational content directly to the clinician’s device. These modules can be completed during quiet moments in a shift or even from home, allowing for a more flexible and personalized approach to professional development. This accessibility ensures that the entire team is always up to date with the latest evidence-based practices and regulatory requirements.

Beyond compliance, these platforms also offer opportunities for career advancement and specialized certification. By tracking the skills and interests of every staff member, the system can suggest training paths that align with their personal professional goals. This commitment to the long-term growth of the individual is a powerful tool for retention and ensures that the institution is constantly building a deeper and more capable talent pool. When a healthcare organization invests in the intellectual and professional development of its staff, it sends a clear signal that it is committed to their long-term success. This culture of learning is essential for maintaining the high standards of care that patients expect and deserve.

Communication, Collaboration and Productivity Tools

Effective communication is the lifeblood of any high-performing care team, yet fragmented and outdated communication methods continue to be a source of frustration and delay in many hospitals. Staff productivity tools are now being used to bridge these gaps, providing a unified and secure platform for real-time collaboration. These tools integrate secure messaging, clinical alerts, and patient data into a single interface, allowing for seamless communication between different departments and specialties. When a nurse can instantly securely message a physician with a clinical concern, or a physical therapist can view the latest surgical notes on their own device, the entire care process becomes more efficient and safer for the patient.

Furthermore, these tools can be used to automate many of the routine communication tasks that currently consume a significant portion of a clinician’s time. For example, the system can automatically send alerts to the appropriate team members when a lab result is ready or when a patient’s vital signs fall outside of a specific range. This “closed-loop” communication ensures that nothing falls through the cracks and that every member of the team has the information they need to provide the best possible care. By reducing the noise and clutter of traditional communication, healthcare workforce technology supporting care teams allows clinicians to focus their attention where it matters most: on the person in the bed. The result is a more calm, organized, and focused clinical environment that is conducive to both healing and professional excellence.

The Impact on Patient Outcomes and Clinical Safety

While the immediate goal of workforce technology is to support the staff, the ultimate beneficiary is always the patient. A well-supported, properly staffed, and highly informed clinical team is far more capable of delivering the high-quality care that leads to positive outcomes. By utilizing digital workforce solutions to optimize staffing levels and reduce burnout, hospitals are directly improving the safety of their patients. The data is clear: institutions with high levels of staff engagement and adequate staffing ratios have lower rates of medical errors, fewer patient falls, and better patient satisfaction scores. The health of the workforce is the single most important predictor of the health of the institution.

Furthermore, the use of workforce technology allows for a more personalized and patient-centered approach to care. When scheduling systems ensure that the right mix of expertise is available on every shift, the hospital can offer more comprehensive and multidisciplinary care for patients with complex needs. This coordinated approach ensures that every aspect of the patient’s health is addressed by a specialist who is well-rested and fully informed. By treating the clinical workforce as a vital and integrated part of the patient care journey, healthcare organizations are ensuring that they can provide the highest standard of medicine for every person who walks through their doors. This is the true power of healthcare workforce technology supporting care teams: it creates a foundation of stability and excellence that supports everything else the hospital does.

Conclusion: The Resilient Future of the Medical Workforce

The ongoing journey of healthcare workforce technology supporting care teams is an investment in the future of medicine itself. We are moving toward a more humanized and sustainable model of healthcare management, where technology acts as a supportive partner rather than an administrative burden. By prioritizing the well-being and professional growth of our clinicians, we are ensuring that the medical profession remains a vibrant and rewarding calling for the next generation. The challenges of the future are significant, but with the right tools and a commitment to our people, we are more than capable of meeting them.

In the end, the success of any healthcare system is measured by the lives it heals and the comfort it provides. This work is only possible through the dedication and skill of the human beings who make up the care team. By building a digital infrastructure that protects, empowers, and supports these individuals, we are ensuring that they have the resources they need to continue their vital mission. This is the promise of modern healthcare workforce management: a future where the clinician is respected, the team is supported, and every patient receives the best possible care from a team that is ready and able to provide it. This is a future we are building one digital tool and one supported shift at a time.

The Historical Context and Technological Leap Forward

To truly appreciate the current state of clinical diagnostics, one must first look back at the origins of radiology. For over a century, the field was defined by the transition from static, two-dimensional shadows to the sophisticated, multi-layered digital environments we see today. The journey from the first rudimentary X-ray to the high-field MRI units of the present day is a testament to human ingenuity. However, the most significant leap has not just been in the hardware itself, but in the software that interprets the massive amounts of data these machines generate. This is where medical imaging innovation improving diagnostic accuracy truly begins to take shape, transforming raw data into actionable clinical insights that save lives daily.

In the early days of medical imaging, the primary challenge was simply getting a clear enough picture to see an abnormality. Radiologists spent years training their eyes to catch the slightest variation in pixel density on a physical film. Today, the challenge has shifted from a lack of data to an overwhelming abundance of it. Modern diagnostic imaging systems produce thousands of slices per scan, creating a volumetric representation of the human body that is so detailed it requires computational assistance to navigate. This shift from physical film to digital volumetric data has laid the groundwork for a more collaborative and precise diagnostic environment, where experts from around the world can view and analyze the same high-fidelity images in real-time.

The Role of Artificial Intelligence in Modern Radiology

Artificial intelligence is no longer a futuristic concept in the world of medicine it is a current reality that is fundamentally altering the workflow of every modern imaging department. AI imaging software serves as a sophisticated filter, identifying patterns that are too subtle for the human eye to consistently detect. These algorithms are trained on datasets containing millions of confirmed clinical cases, allowing them to provide a level of statistical certainty that was previously unattainable. When medical imaging innovation improving diagnostic accuracy is supported by these intelligent systems, the rate of false negatives in critical areas like oncology and cardiology drops significantly, ensuring that patients receive the interventions they need at the earliest possible stage.

The integration of machine learning into radiology innovation goes beyond simple detection. It involves the quantification of disease markers that were previously subjective. For instance, instead of a radiologist estimating the size of a nodule, the software can provide a precise measurement down to the sub-millimeter level, along with an analysis of its density and shape. This level of granularity is essential for tracking the progression of a disease over time. By providing a baseline of objective data, AI imaging software allows clinicians to make more informed decisions about whether a treatment is working or if a change in strategy is required. This synergy between human expertise and machine precision is the hallmark of the modern diagnostic era.

Optimizing the Diagnostic Workflow for Clinical Excellence

Efficiency in the radiology department is not just about speed it is about ensuring that the most critical cases are identified and reviewed with the highest priority. Precision diagnostic workflows leverage automation to triage scans as they are completed. If a system detects a potential intracranial hemorrhage or a pulmonary embolism, it can instantly move that scan to the top of the worklist and alert the on-call specialist. This immediate triaging is a direct result of medical imaging innovation improving diagnostic accuracy, as it reduces the “wait time” for high-stakes diagnoses where every second counts. By optimizing how data flows through the hospital, these systems save lives before a doctor even enters the room.

Furthermore, the reduction of diagnostic fatigue is a significant benefit of these automated systems. Radiologists often review hundreds of scans in a single shift, a task that is mentally and visually taxing. Automation handles the repetitive aspects of the job such as segmenting organs or identifying historical comparisons allowing the specialist to focus their cognitive energy on the complex interpretive work that requires a human touch. This balanced approach not only improves the accuracy of each individual reading but also promotes the long-term well-being of the healthcare workforce. When technology handles the heavy lifting of data processing, the human clinician is empowered to be a more effective healer.

The Personalization of Healthcare Imaging Solutions

Every patient is unique, and the modern approach to diagnostics recognizes that a one-size-fits-all strategy is no longer sufficient. Healthcare imaging solutions are increasingly being tailored to the specific genetic and physiological profile of the individual. For example, in pediatric radiology, the focus is on minimizing radiation exposure while maintaining high diagnostic quality. Advanced reconstruction algorithms can now produce high-resolution images from low-dose scans, protecting the long-term health of young patients. This commitment to “as low as reasonably achievable” (ALARA) principles is a core component of medical imaging innovation improving diagnostic accuracy, as it ensures that the diagnostic process itself does no harm.

In the realm of personalized oncology, imaging is being combined with genomic data to create a comprehensive view of a patient’s health. This field, known as radiomics, extracts thousands of features from medical images that are invisible to the naked eye. These features can predict how a specific tumor will respond to chemotherapy or immunotherapy, allowing doctors to select the most effective treatment from the outset. This move away from trial-and-error medicine toward a more predictive and precise model is perhaps the most exciting frontier of medical imaging technology. It represents a future where the image is not just a snapshot of the present, but a roadmap for the patient’s recovery.

Advancements in Volumetric and Molecular Imaging

The transition from two-dimensional slices to three-dimensional volumetric imaging has revolutionized surgical planning and patient education. Surgeons can now “fly through” a patient’s anatomy using virtual reality tools before they ever step into the operating room. They can identify the exact location of blood vessels, nerves, and tumors, allowing for a more minimally invasive and precise procedure. This level of preparation is a direct outcome of medical imaging innovation improving diagnostic accuracy, as it bridges the gap between the diagnostic suite and the surgical theater. When a surgeon knows exactly what they will encounter, the risk of intraoperative complications is significantly reduced.

Molecular imaging represents the next great hurdle in our understanding of disease. Unlike traditional imaging, which looks at the structure of organs, molecular imaging looks at their function. By using specialized tracers, clinicians can see the metabolic activity of cells in real-time. This is particularly useful for identifying the early stages of neurodegenerative diseases like Alzheimer’s or Parkinson’s, often years before structural changes are visible on a standard scan. The ability to see the “hidden” signals of disease at a molecular level is a testament to the power of radiology innovation. It provides a level of foresight that was previously the stuff of science fiction, allowing for interventions that can slow or even halt the progression of debilitating conditions.

Bridging the Gap: Tele-Radiology and Global Connectivity

The benefits of advanced imaging should not be limited by geography. One of the most significant impacts of modern diagnostic imaging systems is the ability to share data across the globe instantaneously. Tele-radiology platforms allow specialists in metropolitan centers to provide expert interpretations for patients in rural or underserved areas. This democratization of expertise ensures that a patient in a remote village has access to the same high-level diagnostic certainty as a patient in a world-class teaching hospital. This global connectivity is a vital part of medical imaging innovation improving diagnostic accuracy, as it ensures that the best minds in medicine are available whenever and wherever they are needed.

Furthermore, these cloud-based platforms facilitate collaborative research on a scale never before possible. Researchers can pool anonymized imaging data from thousands of institutions to identify new trends and develop more effective diagnostic criteria. This collective intelligence accelerates the pace of innovation, leading to new software tools and hardware improvements that benefit the entire medical community. The synergy between local care and global research creates a feedback loop of continuous improvement, where every scan contributes to a deeper understanding of human health. As we continue to build these digital bridges, the future of radiology looks more connected and more precise than ever before.

Conclusion: The Ethical Imperative of Precision Diagnostics

As we look toward the future, the ongoing medical imaging innovation improving diagnostic accuracy is more than just a technological trend it is an ethical imperative. We have a responsibility to provide patients with the most accurate information possible about their health. Every advancement in software, every improvement in hardware, and every refinement in workflow is a step toward a more just and effective healthcare system. By reducing the margin of error and increasing the speed of diagnosis, we are not just improving metrics we are preserving the human stories that these images represent.

The journey of innovation is never truly complete. There will always be new diseases to understand, new technologies to master, and new ways to improve the patient experience. However, the foundation has been laid. With the integration of AI, the rise of molecular imaging, and the commitment to personalized care, the field of radiology is better equipped than ever to meet the challenges of the 21st century. The ultimate goal remains clear: a world where no diagnosis is missed, every treatment is targeted, and every patient can look forward to a healthy future with confidence. This is the promise of medical imaging technology, and it is a promise we are fulfilling one image at a time.

Under the agreement, Daiichi will obtain exclusive rights to the tool, known as lipodia, representing what could become the company’s first step in extending its cardiovascular portfolio into the digital health sector. The initial rollout of the partnership will focus on the German healthcare market, although the company intends to expand lipodia’s reach to “all major markets on the continent.” The digital solution works by integrating patient-specific, evidence-based behavioural health and psychotherapeutic strategies that guide users toward long-term lifestyle adjustments. Designed to complement pharmaceutical therapy, the system aims to encourage sustained behavioural change while helping reduce a patient’s risk of cardiovascular disease (CVD).

“Digital therapeutics represent an important next step in delivering holistic heart health,” said Oliver Appelhans, Daiichi’s head of EU speciality business. “By combining pharmaceuticals with evidence-based digital therapeutics, we can support patients beyond our medicines.” To support wider access to the therapy, GAIA intends to submit a reimbursement application for lipodia once results from its pivotal Phase III trial become available. Should the application receive approval, Germany’s public health insurers would reimburse the therapy through the country’s Digital Health Applications (DiGA) pathway.

The move reflects a broader trend in the pharmaceutical industry as companies explore how digital technologies can complement drug therapies. Although medications used to treat CVD have significantly improved outcomes, pharmacological treatments alone often do not address the behavioural changes needed for long-term prevention. Estimates suggest that around 80% of heart disease and stroke cases affecting European patients are preventable, highlighting the potential impact of early interventions and educational programmes designed to encourage sustained lifestyle changes. As a result, several pharmaceutical companies are evaluating ways to combine digital health tools and patient education platforms with existing therapies.

Activity in the cardiometabolic health segment illustrates this shift. Novo Nordisk has been exploring collaborations with digital health providers that could offer fitness and dietary guidance alongside treatment with its weight-loss medicine Wegovy (semaglutide). Meanwhile, Otsuka Pharmaceutical currently holds 16% of global revenue in regulator-approved digital health apps. Part of this position is supported by Rejoyn, an application developed with Click Therapeutics and launched in 2024 for patients with depression. The app works alongside the company’s pharmaceutical treatments for major depressive disorder (MDD), including Rexulti (brexpiprazole) and Abilify (aripiprazole).

According to recent analysis from GlobalData, regulator-approved applications are playing a central role in driving growth across the digital health segment, which remains “still in its early stages.” Regulators are also moving to facilitate wider adoption of these technologies. Both the US Food and Drug Administration (FDA) and the UK’s Medicines and Healthcare products Regulatory Authority (MHRA) have introduced policies aimed at encouraging the broader use of digital health tools throughout healthcare systems.

The MHRA stated that it has met 100 per cent of its statutory deadlines for clinical investigation applications since September 2023. In 2025, average approval times stood at 51 days, nine days faster than the 60-day target. The agency said it has also expanded specialist advice meetings for complex technologies, including neurotechnology, cardiac devices, surgical robotics and artificial intelligence.

Neurotechnology emerged as one of the fastest-growing segments. Studies in this area have doubled since 2024 and now account for around a quarter of all UK clinical investigation applications. Recent approvals include a feasibility study exploring whether deep brain stimulation can help treat disorders of addiction, and first-in-human paediatric research led by Great Ormond Street Hospital, University College London and the University of Oxford testing a rechargeable brain stimulation device designed to reduce seizure frequency in children with severe, treatment-resistant epilepsy.

Artificial intelligence-driven medical devices are also increasing. New investigations include systems that scan medical images to detect disease earlier, guide treatment decisions and personalise care. Digital tools that adjust treatment in real time are under study, including an app designed to support people with chronic obstructive pulmonary disease while providing clinicians with enhanced data to tailor therapy. Studies in advanced eye technologies have also risen as companies evaluate new approaches to protect vision and restore sight.

From January 2026, the MHRA introduced a pilot scheme waiving fees for micro and small UK firms to reduce early-stage financial barriers to UK medical device testing . The regulator also announced enhanced support for high-impact technologies and early market access pathways for promising devices.

In addition, the MHRA confirmed it is part of a UK-wide partnership led by Newcastle University to update national guidance on neurotechnology research. The initiative aims to make it quicker and clearer to launch studies involving devices that interact with the brain and nervous system.

MHRA Chief Executive Lawrence Tallon said:
“This has been a standout year for medical device innovation in the UK. We’re seeing more of the world’s most exciting technologies coming here first, particularly in areas like brain health, where patients urgently need better options.

“Our focus now is on backing the most innovative ideas, cutting unnecessary barriers, and helping companies move more quickly while keeping patient safety at the heart of everything we do.”

Mark Grumbridge, Head of Clinical Investigations at the MHRA, said:
“These results reflect the hard work and expertise of our clinical investigations team and our safety assessors; they both worked tirelessly to deliver a faster, more responsive service while maintaining the highest safety standards.

“We’ve expanded specialist advice meetings for complex technologies such as neurotech, cardiac devices, surgical robotics and artificial intelligence. Our door is open for developers to engage with us early so we can help turn promising concepts into real-world clinical investigations.”

Steve Lee, Director of Diagnostics & Digital Regulation at the Association of British HealthTech Industries (ABHI), said:
“The UK’s ability to attract clinical investigations is a key signal of its competitiveness for HealthTech investment and innovation. A timely, transparent and internationally aligned regulatory system enables companies to generate evidence, scale new technologies and deliver benefits to patients and the NHS sooner. We welcome the MHRA’s focus on performance and support for smaller companies.

Clinical investigations are a critical stage in bringing new medical devices from development into clinical use, with regulators assessing safety and effectiveness before wider deployment. The 2025 increase underscores sustained momentum in AI-driven diagnostics, digital health platforms and neurotechnology, as companies seek predictable regulatory timelines and early evidence generation pathways in the UK.

The organisations confirmed that the merger, while financial terms remain undisclosed, will establish what they describe as the largest clinical reporting network in the UK. The combined service is set to span major diagnostic subspecialties and expand capacity to manage both routine and urgent cases.

Medica currently delivers remote teleradiology reporting services to radiology departments across 55% of NHS Trusts. Its clinical focus areas include stroke imaging, cardiac, PET CT, and nuclear medicine, supporting hospitals with off-site specialist expertise.

Axon Diagnostics operates in digital pathology, working with NHS and private healthcare providers to manage caseloads and enable remote reporting workflows. Its cloud-based teleradiology and telepathology platform underpins these services, allowing clinicians to access and report cases remotely.

Through the integration of Axon’s platform and artificial intelligence (AI)-based workflow tools alongside clinical desktop technology from Axon’s sister company, MITIS Medica stated that the enlarged organisation will introduce more streamlined workflows. The aim, it said, is to enhance efficiency and cost effectiveness for clients, in line with the NHS’s long term priorities.

The announcement comes against the backdrop of the UK government’s 10-year plan for the NHS, unveiled in July 2025. In that plan, the UK’s Labour government highlighted the acceleration of AI deployment in hospitals to support clinical reporting in radiology and pathology. The strategy also emphasised remote monitoring to enable virtual care for patients at home.

Medica CEO Andrew Cannon commented: “Bringing Axon into Medica strengthens our position as the UK’s leading diagnostics provider. Clients will continue to receive the excellent service they rely on, now supported by greater capacity and advanced reporting technology.”

To finalise the merger, both companies said they are implementing a phased integration plan designed to bring together their systems, teams, and best practice protocols in a “structured and transparent” manner.

Axon CEO Rahul Mehta commented: “This merger combines our technology and agile approach with Medica’s scale and clinical excellence, meaning more patients will benefit from faster and smarter reporting.”

The transaction also unfolds amid workforce pressures in UK radiology. According to the Royal College of Radiologists (RCR), the country faces a 30% shortfall in clinical radiologists, a figure projected to increase to 40% by 2028 if no corrective measures are taken. In response to these constraints, teleradiology has increasingly served as a key stopgap solution, helping to ease clinician burnout while addressing rising caseloads.

Through the integration, physicians will be able to use natural language queries to search for and retrieve up-to-date clinical data. According to the organizations, the system is built to support quality and safety standards while streamlining how doctors access relevant medical information during patient encounters.

Laura Wilt, Sutter Health’s chief digital officer, said the collaboration reflects a shared ambition to strengthen clinical support and reshape care delivery. She described the effort as part of a broader transformation agenda. “It’s how we’re transforming the way we serve patients, support care teams and improve outcomes,” she said. Wilt added that the organizations are aligned in their commitment to “reimagining healthcare for the better.”

The deployment builds on Sutter Health’s earlier investments in generative AI. Two years ago, the California health system began using generative AI tools with the goal of reducing clinician burnout and enhancing organizational sustainability. At that time, Dr. Albert Chan, Sutter Health’s chief health information officer, said in a statement that the generative AI platform enabled providers to “recharge.”

OpenEvidence, for its part, said the collaboration is intended to move the needle on healthcare sustainability and medical AI safety. Dr. Travis Zack, OpenEvidence’s chief medical officer, indicated that working with Sutter Health advances those objectives.

Clinical decision support has long been associated with improved patient outcomes and more efficient resource utilization. More recently, scientific research has examined whether emerging generative AI technologies can further strengthen performance. Last year, researchers at Mass General Brigham evaluated a hybrid strategy over the course of a yearlong study.

The team compared two large language models (LLMs) – OpenAI’s GPT-4 and Google’s Gemini 1.5 – against the health system’s diagnostic decision support system, DXplain. Findings showed that the established, homegrown platform surpassed the LLMs in diagnostic accuracy for patient cases. However, researchers concluded that combining AI capabilities with traditional decision support systems could yield stronger results.

In their report, the MGB researchers detailed how pairing DXplain with an LLM could enhance the clinical efficacy of both systems. “A hybrid approach that combines the parsing and expository linguistic capabilities of LLMs with the deterministic and explanatory capabilities of traditional DDSSs may produce synergistic benefits,” they said.

Sutter Health executives framed the OpenEvidence integration as part of a broader digital strategy. “Digital innovation plays a central role in our work to build a more connected, proactive and sustainable healthcare system,” Wilt said in the announcement. Dr. Ashley Beecy, Sutter Health’s chief AI officer, underscored the patient impact, stating, “Patients benefit when providers have the most current and relevant evidence incorporated into clinical decision-making,” she added.